Johnson T Mark, Glaser Bert M
National Retina Institute, Chevy Chase, MD 20815, USA.
Retina. 2006 Sep;26(7):765-72. doi: 10.1097/01.iae.0000244264.98642.af.
To evaluate the feasibility of focal laser ablation of retinal angiomatous proliferation (RAP) identified with clinical examination and high-speed indocyanine green (ICG) imaging in patients with age-related macular degeneration.
In this retrospective, interventional case series, 16 consecutive eyes of 15 patients with macular degeneration and leakage from a stage I or II RAP lesion were identified. RAP lesions were identified using clinical examination and high-speed ICG imaging. High-speed ICG imaging was used to identify the intraretinal component of the lesion. RAP lesions were treated with a 100- to 200-mum green or yellow wavelength laser spot that was applied to completely ablate the intraretinal component of the lesion. In eyes with stage II lesions, the subretinal component of the lesion was not treated. Early Treatment of Diabetic Retinopathy Study visual acuity, optical coherence tomography retinal thickness, angiographic leakage, and progression of the angiomatous process shown by ICG imaging were evaluated preoperatively and postoperatively.
Sixteen eyes underwent successful ablation of the RAP lesions with an average of 1.9 treatment sessions. At a mean follow-up of 15.5 months, 94% of eyes had stable or improved visual acuity. Only 6% of eyes had a loss of >or=3 lines of visual acuity. The average visual acuity at the last follow-up was 20/45 in the stage I lesion group and 20/160 in the stage II lesion group. Of the patients, 87.5% had a reduction in retinal edema and subretinal fluid, with 69% of patients having complete resolution of retinal edema and subretinal fluid; 14% of patients had progression to retinal choroidal anastomoses. No treatment complications were encountered.
Focal laser photocoagulation of RAP lesions appears to be feasible. This treatment appears to be a safe method of managing the leakage from RAP. Treatment of solely the intraretinal component of the lesion may be adequate to control leakage. Treatment may allow the angiomatous process to be arrested, resulting in stabilization of visual acuity. Visual acuity results appear to be better for patients with early stage lesions.
评估在年龄相关性黄斑变性患者中,通过临床检查和高速吲哚菁绿(ICG)血管造影成像识别出的视网膜血管瘤样增殖(RAP)进行局灶性激光消融的可行性。
在这个回顾性的介入性病例系列中,确定了15例黄斑变性患者的16只眼睛,这些眼睛存在I期或II期RAP病变并伴有渗漏。通过临床检查和高速ICG血管造影成像来识别RAP病变。使用高速ICG血管造影成像来识别病变的视网膜内成分。对RAP病变采用100至200微米的绿色或黄色波长激光光斑进行治疗,以完全消融病变的视网膜内成分。对于II期病变的眼睛,不治疗病变的视网膜下成分。术前和术后评估糖尿病视网膜病变早期治疗研究视力、光学相干断层扫描视网膜厚度、血管造影渗漏以及ICG血管造影显示的血管瘤样病变进展情况。
16只眼睛成功消融了RAP病变,平均治疗1.9次。平均随访15.5个月时,94%的眼睛视力稳定或提高。只有6%的眼睛视力下降≥3行。I期病变组最后一次随访时的平均视力为20/45,II期病变组为20/160。87.5%的患者视网膜水肿和视网膜下液减少,69%的患者视网膜水肿和视网膜下液完全消退;14%的患者进展为视网膜脉络膜吻合。未出现治疗并发症。
RAP病变的局灶性激光光凝似乎是可行的。这种治疗似乎是处理RAP渗漏的一种安全方法。仅治疗病变的视网膜内成分可能足以控制渗漏。治疗可能使血管瘤样病变停止发展,从而使视力稳定。早期病变患者的视力结果似乎更好。